This is the first description tracking the development of resistance mutations in a patient with non‐myofibroblastic sarcoma and questions the utility of the presence of G1202R mutation as a marker of lorlatinib sensitivity in non‐lung ALK rearranged tumours, contrary to experience in lung cancer. This evidence concerns the gene ALK and lung cancer.